Access cutting-edge stxbp1 encephalopathy treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.
Access stxbp1 encephalopathy specialists in Houston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related stxbp1 encephalopathy treatment provided free
The goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether CAP-002 demonstrates efficacy in treating children with STXBP1 with and without seizures. Participants will have a single infusion of CAP-002, visit the clinic regularly for 2 years for checkups and tests and have seizures recorded in a diary by their caregiver.
Sponsor: Capsida Biotherapeutics, Inc.
Check if you qualify for this stxbp1 encephalopathy clinical trial in Houston, TX
If you're searching for stxbp1 encephalopathy treatment options in Houston, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stxbp1 encephalopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.